Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have been given an average recommendation of “Hold” by the twenty-five research firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $11.39.
Several analysts recently issued reports on TEVA shares. Barclays restated a “sell” rating and issued a $9.00 price objective on shares of Teva Pharmaceutical Industries in a report on Friday, April 17th. UBS Group upped their price target on Teva Pharmaceutical Industries from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Bank of America restated an “underperform” rating and issued a $8.00 price target (up previously from $7.00) on shares of Teva Pharmaceutical Industries in a research report on Friday, May 8th. Morgan Stanley decreased their price target on Teva Pharmaceutical Industries from $13.00 to $8.00 and set an “underweight” rating on the stock in a research note on Thursday, April 2nd. Finally, SunTrust Banks upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their target price for the company from $11.00 to $16.00 in a report on Monday, June 1st.
Shares of TEVA opened at $12.18 on Friday. The company has a market cap of $13.31 billion, a P/E ratio of -16.03, a P/E/G ratio of 0.86 and a beta of 1.64. Teva Pharmaceutical Industries has a twelve month low of $6.07 and a twelve month high of $13.76. The company’s fifty day simple moving average is $12.17 and its 200-day simple moving average is $10.65. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.68.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.17. Teva Pharmaceutical Industries had a negative net margin of 4.73% and a positive return on equity of 18.10%. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.15 billion. During the same period last year, the business earned $0.60 EPS. The company’s revenue was up 5.0% compared to the same quarter last year. Analysts predict that Teva Pharmaceutical Industries will post 2.4 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Sunbelt Securities Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $6,827,000. First National Bank of South Miami bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $31,000. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in Teva Pharmaceutical Industries by 329.9% during the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 4,020 shares of the company’s stock worth $39,000 after purchasing an additional 3,085 shares during the period. Advisory Alpha LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 161.8% during the first quarter. Advisory Alpha LLC now owns 4,045 shares of the company’s stock worth $41,000 after acquiring an additional 2,500 shares during the period. Finally, NEXT Financial Group Inc raised its position in shares of Teva Pharmaceutical Industries by 77.0% in the first quarter. NEXT Financial Group Inc now owns 6,824 shares of the company’s stock valued at $61,000 after buying an additional 2,969 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: What is the Bid-Ask Spread?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.